Why you value a bank, a cyclical and a compounder differently

Imagine handing the same valuation toolkit to three investors and pointing each at a different company — a bank, a steelmaker, and a steadily-growing consumer brand. If all three reach for the P/E and compare the numbers head to head, two of them will reach badly wrong conclusions. Not because they did the arithmetic poorly, but because they used the wrong yardstick for the kind of business in front of them. The tools don't change; the business does — and the business decides which tool tells the truth.

This is the lesson that ties the whole module together. A multiple isn't right or wrong in the abstract; it's right or wrong for a particular kind of business. So let's take three archetypes that behave so differently they practically demand different mental models, and see how the same questions land in three different places.

The bank: a business that is its balance sheet

A bank looks like a normal company from the outside, but its economics are inside-out. Its raw material is money: it borrows from depositors, lends to borrowers, and earns the spread between the two. Its entire value sits in a giant book of loans and the capital cushioning them. That single fact reshapes how you value it.

First, a bank's earnings are treacherous. In a good year, loans get repaid and profit looks splendid. In a bad year, a wave of loans goes sour and the bank must set aside huge provisions against them — and profit can collapse or vanish, even though the franchise is intact. So a P/E on a bank lurches violently from year to year and often misleads. That's why investors anchor on P/B instead: book value — the bank's net worth — is far steadier than its profit, and it's the natural measure of a business whose value is its balance sheet.

But P/B alone is a half-truth, because a bank's book value is only as real as its loans are collectible. This is where the genuinely bank-specific yardsticks come in, and they're worth knowing by name.

• Asset quality — what fraction of the loans are going bad? Investors watch non-performing loans obsessively, because a book stuffed with souring loans is worth far less than its stated value.
• Net interest margin — the spread between what the bank earns on loans and pays on deposits. It's the core profitability of the lending engine.
• Return on equity — how much profit the bank squeezes from its capital, which, paired with P/B, tells you whether a premium to book is deserved.

The cyclical: a business at the mercy of its cycle

Now the opposite trap. A cyclical — a steelmaker, a cement producer, an automaker, a commodity miner — sells into a market whose prices and demand swing in great waves. When the cycle is hot, prices soar, factories run flat out, and profits balloon. When it turns cold, prices crash, plants run half-empty, and profits evaporate or turn to losses. The business hasn't changed; the cycle has.

This wrecks the P/E in a uniquely cruel way. At the top of the cycle, profits are at a fat, unsustainable peak — so the P/E looks lowest exactly when the stock is most dangerous. A naive bargain-hunter sees a steelmaker on a P/E of 5 at the peak and buys, just as profits are about to collapse and the 'cheap' P/E balloons into a huge one as the 'E' falls away. At the bottom, profits are squeezed to nothing or negative, so the P/E looks enormous or undefined — exactly when the stock may be a genuine bargain.

So how do you value a cyclical? You stop trusting any single year's profit and think in terms of the whole cycle. The professional's instinct is to estimate normalised or mid-cycle earnings — roughly, what the business earns on average across good years and bad — and value it on that, not on a peak or a trough. P/B and EV/EBITDA also help here, because asset value and pre-financing cash are steadier than the wildly swinging bottom line. The mental shift is everything: with a cyclical, you're not valuing this year, you're valuing an average year repeated through the ups and downs.

The compounder: a business that grows its own value

Finally, the kind of business investors dream about: the compounder — a high-quality firm earning strong, durable returns on capital, protected by a moat, able to reinvest its profits at those same high returns year after year. Think of a beloved consumer brand or a dominant software platform that grows steadily and throws off cash. Here the valuation challenge inverts yet again.

A compounder almost always looks expensive on a snapshot P/E, and that optical expensiveness scares away the very investors who'd most benefit from owning it. The reason it can still be a wonderful buy is the engine we met earlier: a business reinvesting at 25% returns turns each retained rupee into far more future profit, so its earnings grow and grow, and the high P/E you paid shrinks in the rear-view mirror as the 'E' swells beneath it.

Valuing a compounder is therefore less about the current multiple and more about durability. The questions that matter are different from a bank's or a cyclical's:

• How durable is the moat? Will the high returns survive a decade of competition, or fade in three years?
• How long is the runway? Can the company keep reinvesting large sums at high returns, or will it soon run out of profitable places to put the money?
• Is the quality real? High returns on capital with low debt and steady cash conversion — or growth bought with borrowed money and accounting flattery?

Same questions, different weights

Notice what's really going on across all three. You aren't using three unrelated methods — you're asking the same underlying question (what cash can this business return over its life, and what's that worth today?) but shifting which sub-question carries the weight. For the bank, the weight is on the quality of the balance sheet. For the cyclical, it's on where we are in the cycle and what a normal year looks like. For the compounder, it's on how durable the growth and returns are. The multiple you lead with — P/B, normalised P/E or EV/EBITDA, forward-looking quality judgement — simply follows from which question matters most.

This is the quiet sophistication that separates a thoughtful investor from a ratio-reciter. The beginner asks 'what's the P/E?' and stops. The thoughtful investor asks 'what kind of business is this, and therefore which yardstick will actually tell me the truth?' — and only then reaches for a number. There is no universal formula because there is no universal business. A bank, a cyclical and a compounder are three different animals, and valuing them as though they were the same is the surest way to be precisely, confidently wrong. Match the lens to the business, weigh the right question heaviest, and demand a margin of safety against the judgement you're least sure of. That, in the end, is valuation without the jargon.